

02-24-04

Express Mail Label No.: EL928105093US

Date of Deposit: February 23, 2004

RCE# 1646

PTO/SB/30 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Request  
For  
Continued Examination (RCE)  
Transmittal**

Address to:  
Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Application Number	09/924,125
Filing Date	August 7, 2001
First Named Inventor	Communi
Art Unit	1646
Examiner Name	Li, R.
Attorney Docket Number	9409/2092

RECEIVED

MAR 01 2004

**This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application.**

Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2.

1. **Submission required under 37 CFR 1.114** Note: If the RCE is proper, any previously filed unentered amendments and amendments enclosed with the RCE will be entered in the order in which they were filed unless applicant instructs otherwise. If applicant does not wish to have any previously filed unentered amendment(s) entered, applicant must request non-entry of such amendment(s).

a. ☐ Previously submitted. If a final Office action is outstanding, any amendments filed after the final Office action may be considered as a submission even if this box is not checked.

i. ☐ Consider the arguments in the Appeal Brief or Rely Brief previously filed on \_\_\_\_\_

ii. ☐ Other \_\_\_\_\_

b. ☒ Enclosed

i. ☒ Amendment/Reply

iii. ☐ Information Disclosure Statement (IDS)

ii. ☐ Affidavit(s)/ Declaration(s)

iv. ☐ Other \_\_\_\_\_

2. **Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of \_\_\_\_\_ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required)

b. ☐ Other \_\_\_\_\_

3. **Fees**

The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed.

The Director is hereby authorized to charge the following fees, or credit any overpayments, to

a. ☒ Deposit Account No. 16-0085, Ref. 9409/2092

i. ☒ RCE fee required under 37 CFR 1.17(e)

02/26/2004 JADD01 00000066 160085 09924125

ii. ☒ Extension of time fee (37 CFR 1.136 and 1.17)

01 FC:2801 385.00 DA

iii. ☐ Other \_\_\_\_\_

b. ☐ Check in the amount of \$ \_\_\_\_\_ enclosed

c. ☐ Payment by credit card (Form PTO-2038 enclosed)

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

Name (Print/Type)	Kathleen Williams	Registration No. (Attorney/Agent)	34,380
Signature		Date	February 23, 2004


**CERTIFICATE OF MAILING OR TRANSMISSION**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as **express mail** addressed to: Mail Stop RCE, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below.

Name (Print/Type)	Mary Wilson	Date	February 23, 2004
Signature			

This collection of information is required by 37 CFR 1.114. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail Label No.: EL928105093US

Date of Deposit: February 23, 2004

Atty. Docket No.: 9409/2092

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Communi et al.  
Serial No.: 09/924,125  
Filed: August 7, 2001  
Titled: The Natural Ligand for Orphan G-protein Coupled Receptor GPR86 and Methods of Use

Examiner: Li, R.

Group Art Unit: 1646

Conf. No.: 3058

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RECEIVED

MAR 01 2004

AMENDMENT AFTER FINAL REJECTION UNDER 37 C.F.R. 1.116

Sir:

This Amendment is being filed in response to the Office Action mailed from the U.S. Patent and Trademark Office on August 21, 2003 in the above-identified application. Reconsideration and further examination are requested. An extension of time and a Notice of Appeal from the Final Office Action dated August 21, 2003, with appropriate fees, are being filed concurrently.

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are shown in the "Listing of the Claims" which begins on page 4 of this paper.

**Remarks** begin on page 7 of this paper.

Applicants respectfully request entry of the amendments and remarks.